Colorectal cancer is third most common cancer in men and second most common in women with over 1.3 million new cases annually on a worldwide basis. An estimated 694,000 deaths from CRC occur worldwide every year, accounting for 8.5% of all cancer deaths and making it the fourth most common cause of death from cancer.

Why study miR-31-3p in metastatic colorectal cancer?

  •  Over 1.3 million new cases annually on a worldwide basis. Over 275,000 new cases in Europe and 135,000 new cases in the U.S. on an annual basis.1
  •  25% of patients with colorectal cancer will present with metastatic disease with up to 50% developing mCRC following initial diagnosis.2

While anti-EGFR (epidermal growth factor receptor) therapy is not indicated for approximately 50% of patients with metastatic colorectal cancer (mCRC) since they carry a RAS mutation which makes them non-responsive to these agents, anti-EGFRs remain an option for RAS wild-type (WT) patients. Unfortunately, the response to these agents is variable in this patient population.

The discovery and development of the miR-31-3p biomarker for patients with mRC is based on original research led by Pierre Laurent-Puig, M.D., Ph.D., Professor, Department of Genetics and head of the Clinical Oncogenetic Unit, European Georges Pompidou Hospital, University Paris Descartes, Paris, France.

.

miRpredX 31-3p is a predictive biomarker that identifies patients with mCRC who have improved outcomes when treated with anti-EGFR therapy


  • Low miR-31-3p expression is associated with a 40% reduced risk of death and a 13 month survival advantage with anti-EGFR (cetuximab) therapy versus anti-VEGF (bevacizumab) therapy which uses as 1st line biologic therapy in patients with mCRC.3
  • miR-31-3p expression predicts response to anti-EGFR therapy for multiple patient outcomes.3,4

.

Over 5 years of development with data from over 850 patients from 9 independent patient cohorts


  • Includes positive data associated with the analysis of FFPE tumor samples from 3 separate prospective, randomized Phase III trials enrolling patients with mCRC.
  • Multiple presentations of data at key oncology meetings in Europe and the U.S.
  • Click here to review the results of studies to date which have demonstrated the predictive effect miR-31-3p expression has on response to EGFR inhibitors in patients with mCRC.

 


  1. World Health Organization – International Agency for Research on Cancer, 2016
  2. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D for the ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii1-9. 
  3. Laurent-Puig P, Grisoni ML, Heinemann V, et al. miR-31-3p as a predictive biomarker of cetuximab efficacy effect in metastatic colorectal cancer (mCRC) patients enrolled in FIRE-3 study.  J Clin Oncol. 201634 (suppl; abstr 3516)
  4. Laurent-Puig P, Paget-Bailly S, Vernerey D, et al. Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit inRAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial (abstract). J Clin Oncol. 2015; 33 (Suppl. 15): 3547